JP6651466B2 - Production method of yeast fermented liquid, composition and raw material using swallow nest as raw material - Google Patents
Production method of yeast fermented liquid, composition and raw material using swallow nest as raw material Download PDFInfo
- Publication number
- JP6651466B2 JP6651466B2 JP2016572943A JP2016572943A JP6651466B2 JP 6651466 B2 JP6651466 B2 JP 6651466B2 JP 2016572943 A JP2016572943 A JP 2016572943A JP 2016572943 A JP2016572943 A JP 2016572943A JP 6651466 B2 JP6651466 B2 JP 6651466B2
- Authority
- JP
- Japan
- Prior art keywords
- yeast
- fermentation
- raw material
- nest
- swallow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002994 raw material Substances 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims 16
- 239000002131 composite material Substances 0.000 title 1
- 239000011344 liquid material Substances 0.000 title 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 45
- 238000000855 fermentation Methods 0.000 claims description 39
- 230000004151 fermentation Effects 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 28
- 241000167880 Hirundinidae Species 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 235000015872 dietary supplement Nutrition 0.000 claims description 16
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 13
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000004296 neuralgia Diseases 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 235000021067 refined food Nutrition 0.000 claims description 9
- 235000005770 birds nest Nutrition 0.000 claims description 8
- 235000005765 wild carrot Nutrition 0.000 claims description 8
- 244000000626 Daucus carota Species 0.000 claims description 7
- 208000004454 Hyperalgesia Diseases 0.000 claims description 7
- 206010053552 allodynia Diseases 0.000 claims description 7
- 235000014214 soft drink Nutrition 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 4
- 241000235343 Saccharomycetales Species 0.000 claims 2
- 244000286779 Hansenula anomala Species 0.000 description 31
- 239000000047 product Substances 0.000 description 22
- 235000013305 food Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 11
- 241000255927 Papilio polyxenes Species 0.000 description 10
- 241000235070 Saccharomyces Species 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000023589 ischemic disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000397426 Centroberyx lineatus Species 0.000 description 4
- 240000007357 Nauclea orientalis Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000004099 anaerobic respiration Effects 0.000 description 3
- 230000003574 anti-allodynic effect Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 241000429775 Acraea rogersi Species 0.000 description 2
- 241001578852 Aegla franca Species 0.000 description 2
- 241000203244 Aerodramus brevirostris Species 0.000 description 2
- 241000352200 Aerodramus hirundinaceus Species 0.000 description 2
- 241000011480 Aerodramus papuensis Species 0.000 description 2
- 241000203250 Aerodramus salangana Species 0.000 description 2
- 241000203248 Aerodramus sawtelli Species 0.000 description 2
- 241000203256 Aerodramus spodiopygius Species 0.000 description 2
- 241000999994 Aerodramus vanikorensis Species 0.000 description 2
- 241001225657 Aerodramus vulcanorum Species 0.000 description 2
- 241000999993 Aerodramus whiteheadi Species 0.000 description 2
- 241000062811 Apus unicolor Species 0.000 description 2
- 241000940786 Atherigona soccata Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 241001304241 Hirundo angolensis Species 0.000 description 2
- 241000034246 Leucophaeus Species 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- -1 penetrants Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000203186 Collocalia troglodytes Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000178951 Endomyces Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001159781 Kazachstania spencerorum Species 0.000 description 1
- 241000039979 Kazachstania turicensis Species 0.000 description 1
- 241001123232 Kazachstania unispora Species 0.000 description 1
- 241000965982 Kazachstania zonata Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241000235087 Lachancea kluyveri Species 0.000 description 1
- 241000937897 Meyerozyma caribbica Species 0.000 description 1
- 241001123224 Naumovozyma dairenensis Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000235072 Saccharomyces bayanus Species 0.000 description 1
- 241000198071 Saccharomyces cariocanus Species 0.000 description 1
- 241000877399 Saccharomyces chevalieri Species 0.000 description 1
- 235000018370 Saccharomyces delbrueckii Nutrition 0.000 description 1
- 241000877401 Saccharomyces ellipsoideus Species 0.000 description 1
- 241001407717 Saccharomyces norbensis Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000582914 Saccharomyces uvarum Species 0.000 description 1
- 241000235003 Saccharomycopsis Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 241001278026 Starmerella bombicola Species 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 244000288561 Torulaspora delbrueckii Species 0.000 description 1
- 235000014681 Torulaspora delbrueckii Nutrition 0.000 description 1
- 241000684582 Torulaspora microellipsoides Species 0.000 description 1
- 241001504501 Troglodytes Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- 241000192248 [Candida] saitoana Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、アナツバメ巣を原材料とする素材、組成物及び素材の製造方法に関する。 The present invention relates to a material, a composition, and a method for producing a material using a swallow nest as a raw material.
従来知られる天然物を原料として生み出された素材は、その機能性についても原料から予想される範囲を超えないことが多い。しかしながら原料の組み合わせ方、組み合わせた原料の処理方法、又は処理された原料の精製方法によって、その原料から機能性を有する未知の素材を生み出し得ることが知られている。 Materials produced using conventionally known natural products as raw materials often do not exceed the range expected from the raw materials in terms of functionality. However, it is known that an unknown material having functionality can be produced from the raw material by a method of combining the raw materials, a method of treating the combined raw materials, or a method of purifying the processed raw materials.
特許文献１はアナツバメ巣の酵素分解物を有効成分として含有する美肌促進剤を開示している。かかる美肌促進剤は酵母を培養して得られる培養物をさらに含有する。 Patent Literature 1 discloses a skin-beautifying agent containing an enzymatically decomposed product of a swallow's nest as an active ingredient. Such a beautiful skin promoting agent further contains a culture obtained by culturing yeast.
本発明は、天然物を原料とするとともに、機能性を有することが期待される未知の素材を提供することを目的としている。 An object of the present invention is to provide an unknown material that is expected to have functionality while using a natural product as a raw material.
本発明の一態様に係る素材はアマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物である。前記酵母発酵物は医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水のいずれかとして使用されることが好ましい。 The material according to one embodiment of the present invention is a yeast fermented product of a bird's nest belonging to the genus Swallows. The yeast fermented product is preferably used as any of medicines, quasi-drugs, health supplement foods, nutritional supplement foods, processed foods, and soft drinks.
本発明の一態様はアマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物を含有する組成物である。前記組成物は医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水のいずれかであることが好ましい。 One embodiment of the present invention is a composition containing a fermented yeast product of a bird's nest belonging to the genus Swallows of the family Swift. The composition is preferably any one of a medicine, a quasi-drug, a food for health supplement, a food for nutrition supplement, a processed food, and a soft drink.
前記組成物はアロディニア又は神経因性疼痛を改善するための組成物であることが好ましい。前記組成物は生活習慣病の予防及び改善のうち少なくとも一方のための組成物であることが好ましい。前記生活習慣病は糖尿病、高血圧症、心虚血疾患及び脳虚血疾患のうちの少なくともいずれか一つであることが好ましい。前記組成物はウイルス感染を防ぐための組成物であることが好ましい。 Preferably, the composition is a composition for ameliorating allodynia or neuropathic pain. The composition is preferably a composition for at least one of prevention and improvement of lifestyle-related diseases. Preferably, the lifestyle-related disease is at least one of diabetes, hypertension, cardiac ischemic disease and cerebral ischemic disease. The composition is preferably a composition for preventing viral infection.
本発明の一態様はアマツバメ科アナツバメ属に属する鳥の巣を原料とする、素材製造方法である。かかる方法では前記原料に酵母を添加する。また前記原料を前記酵母で発酵させる。発酵前の前記原料に水分を添加することが好ましい。前記原料を前記水分とともに発酵させることが好ましい。発酵は密閉状態で行うことが好ましい。発酵後、前記水分の少なくとも一部を蒸発させることが好ましい。 One embodiment of the present invention is a method for producing a raw material using a bird's nest belonging to the genus Swallows in the family Swallows. In such a method, yeast is added to the raw material. The raw material is fermented with the yeast. It is preferable to add water to the raw material before fermentation. Preferably, the raw material is fermented together with the water. Fermentation is preferably performed in a closed state. After fermentation, it is preferable to evaporate at least a part of the water.
本発明の一態様は、糖尿病、高血圧症、心虚血疾患、脳虚血疾患、ウイルス感染、病原微生物感染、過労及び栄養失調、記憶障害、皮膚の乾燥、皮膚の乾燥に伴うシワの形成、アロディニア及び神経因性疼痛のいずれかに罹患している患者への、アマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物の投与である。 One embodiment of the present invention is diabetes, hypertension, cardiac ischemic disease, cerebral ischemic disease, viral infection, pathogenic microbial infection, overwork and malnutrition, memory impairment, dry skin, wrinkle formation associated with dry skin, allodynia And the administration of a yeast fermentation of a bird's nest belonging to the genus Swallows, to a patient suffering from any of the following diseases.
本発明の一態様は、医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水のいずれかの製造のための、アマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物の使用である。 One embodiment of the present invention provides a bird's nest yeast belonging to the genus Swallows, for the manufacture of any of pharmaceuticals, quasi-drugs, foods for health supplements, foods for nutritional supplements, processed foods, and soft drinks. Use of fermented products.
本発明は、天然物を原料とするとともに、機能性を有することが期待される未知の素材を提供することができる。 INDUSTRIAL APPLICABILITY The present invention can provide an unknown material which is expected to have functionality while using a natural product as a raw material.
以下、本発明の実施を説明する。 Hereinafter, embodiments of the present invention will be described.
本実施形態において「天然物」とは生物が産生する物質をいう。生物は動物、植物及び微生物を含む。生物は人工的に育種されたものでもよい。生物が産生する物質は人工的に得られるものでもよい。生物は自然物でもよい。生物が産生する物質は自然物でもよい。本実施形態において自然物とは人工の物又は人為的な物でなく自然界に存在する物をいう。すなわち発明の実施にあたり自然界から取得されるものをいう。 In this embodiment, “natural product” refers to a substance produced by an organism. Organisms include animals, plants and microorganisms. The organism may be artificially bred. The substance produced by an organism may be artificially obtained. The living thing may be a natural thing. The substance produced by an organism may be a natural substance. In the present embodiment, a natural object refers to an object existing in the natural world, not an artificial object or an artificial object. That is, what is obtained from the natural world when implementing the invention.
本実施形態において「素材」の用語は組成物に配合されるのに適する物質をいう。本実施形態において「機能性素材」の用語は素材のうち、生体に何らかの好ましい影響を与える効果を有する、又は有することが期待される素材をいう。「機能性素材」の用語にはこれらの組成物の付加価値を高める目的で配合される素材が含まれる。機能性素材は天然物を原料として生み出された物質であることが好ましい。 In this embodiment, the term "material" refers to a substance suitable for being blended into the composition. In the present embodiment, the term “functional material” refers to a material that has, or is expected to have, an effect of giving a desirable effect to a living body, among materials. The term "functional material" includes materials formulated for the purpose of increasing the added value of these compositions. The functional material is preferably a substance produced from natural products as a raw material.
組成物は医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水のいずれかであることが好ましい。「医薬品」及び「医薬部外品」の用語には漢方薬が含まれる。「健康補助用食品」、「栄養補助用食品」及び「加工食品」の用語には高栄養食品が含まれる。上記素材は上記組成物に添加される素材であることが好ましい。素材は機能性素材であることが好ましい。 Preferably, the composition is any of a pharmaceutical, a quasi-drug, a food for health supplement, a food for nutrition supplement, a processed food, and a soft drink. The terms "medicine" and "quasi-drug" include herbal medicines. The terms "health supplement," "dietary supplement," and "processed food" include high nutrition foods. The material is preferably a material added to the composition. The material is preferably a functional material.
本実施形態にかかる素材はアマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物である。以下、アマツバメ科アナツバメ属に属する鳥を、アナツバメ属という場合がある。 The material according to the present embodiment is a fermented yeast product of a bird's nest belonging to the genus Swallows of the family Swift. Hereinafter, birds belonging to the genus Swallows may be referred to as genus Swallows.
「酵母発酵物」の用語は原料を酵母の存在下で発酵させた状態の物を表す。「酵母」の用語は例えば出芽酵母（Ｓａｃｃｈａｒｏｍｙｃｅｓ ｃｅｒｅｃｉｓｉａｅ）を含むがこれに限定されない。「発酵」の用語は酵母の嫌気呼吸を伴う、酵母による原料の分解を含む。酵母発酵物は酵母による原料の分解物である。 The term “yeast fermented product” refers to a product obtained by fermenting a raw material in the presence of yeast. The term "yeast" includes, but is not limited to, for example, Saccharomyces cerecisiae. The term "fermentation" includes the decomposition of raw materials by yeast, with anaerobic respiration of yeast. A yeast fermentation product is a decomposition product of a raw material by yeast.
本実施形態にかかる組成物は上記素材を含有する上記組成物である。かかる組成物は、糖尿病、高血圧症、心虚血疾患及び脳虚血疾患を含む生活習慣病に伴う症状、ウイルス感染及び病原微生物感染を含む病原体感染に伴う症状、過労及び栄養失調を含む生活要因に伴う症状、記憶障害並びに皮膚の乾燥及びそれに伴うシワの形成からなる群から選ばれる一以上の症状の予防及び改善のうち少なくとも一方のために使用してもよい。 The composition according to the present embodiment is the above composition containing the above materials. Such compositions may reduce the symptoms associated with lifestyle-related diseases, including diabetes, hypertension, cardiac ischemic disease and cerebral ischemic disease, the symptoms associated with pathogen infections, including viral and pathogenic microbial infections, and life factors, including overwork and malnutrition. It may be used to prevent and / or ameliorate one or more symptoms selected from the group consisting of associated symptoms, memory impairment, and dry skin and wrinkle formation associated therewith.
上記症状を呈する患者に組成物を投与してもよい。投与は経口投与でもよい。 The composition may be administered to a patient exhibiting the above symptoms. Administration may be oral.
本実施形態にかかる素材製造方法では、アナツバメ属の巣を原料とする。かかる方法では前記原料に酵母を添加し、前記原料とともに前記酵母を培養する。 In the material manufacturing method according to the present embodiment, a nest of the genus Swallow is used as a raw material. In such a method, yeast is added to the raw material, and the yeast is cultured with the raw material.
好適なアナツバメ属には、Ａ．ａｍｅｌｉｓ（ハイイロアナツバメ）、Ａ．ｂｒｅｖｉｒｏｓｔｒｉｓ（ヒマラヤアナツバメ）、Ａ．ｅｌａｐｈｒａ（セイシェルアナツバメ）、Ａ．ｆｒａｎｃｉｃａ（ショクヨウアナツバメ）、Ａ．ｆｕｃｉｐｈａｇａ（ジャワアナツバメ）、Ａ．ｇｅｒｍａｎｉ（マレーアナツバメ）、Ａ．ｈｉｒｕｎｄｉｎａｃｅａ（ヤマアナツバメ）、Ａ．ｉｎｆｕｓｃａｔａ（モルッカアナツバメ）、Ａ．ｉｎｑｕｉｅｔａ（カロリンアナツバメ）、Ａ．ｌｅｕｃｏｐｈａｅｕｓ（タヒチアナツバメ）、Ａ．ｍａｘｉｍａ（オオアナツバメ）、Ａ．ｍｅａｒｎｓｉ（フィリピンムジアナツバメ）、Ａ．ｎｕｄｉｔａｒｓｕｓ（パプアヤマアナツバメ）、Ａ．ｏｃｉｓｔａ（マルケサスアナツバメ）、Ａ．ｏｒｉｅｎｔａｌｉｓ（ガタルカナルアナツバメ）、Ａ．ｐａｌａｗａｎｅｎｓｉｓ（パラワンムジアナツバメ）、Ａ．ｐａｐｕｅｎｓｉｓ（パプアカワアナツバメ）、Ａ．ｐｅｌｅｗｅｎｓｉｓ（ミクロネシアムジアナツバメ）、Ａ．ｒｏｇｅｒｓｉ（インドシナアナツバメ）、Ａ．ｓａｌａｎｇａｎａ（コケアナツバメ）、Ａ．ｓａｗｔｅｌｌｉ（クックアナツバメ）、Ａ．ｓｐｏｄｉｏｐｙｇｉｕｓ（コシジロアナツバメ）、Ａ．ｔｅｒｒａｅｒｅｇｉｎａｅ（オーストラリアアナツバメ）、Ａ．ｕｎｉｃｏｌｏｒ（インドショクヨウアナツバメ）、Ａ．ｗｈｉｔｅｈｅａｄｉ（フィリピンアナツバメ）、Ａ．ｖａｎｉｋｏｒｅｎｓｉｓ（ムジアナツバメ）、Ａ．ｖｕｌｃａｎｏｒｕｍ（ミヤマアナツバメ）、Ｃ．ｅｓｃｕｌｅｎｔａ（シロハラアナツバメ）、Ｃ．ｌｉｎｃｈｉ（ドウクツアナツバメ）及びＣ．ｔｒｏｇｌｏｄｙｔｅｓ（コビトアナツバメ）が含まれる。 Suitable Swallows include A. amelis (A. swallowtail), A. brevirostris (Himalayan Swallows), A. elaphra (Seychelles Swallow), A. franca (A. swallowtail), A. fuciphaga (Swallow Swallow), A. germani (Malayan swallow), A. hirundinacea (Sweet Swallow), A. infuscata (Molkka swallow), A. inquieta (carolin swallow), A. leucophaeus (Tahitian swallows); maxima (Big Swallow), A. meansi (Philippines swallow), A. nuditarsus (Papua yamaswallow), A. ocista (Marquesas swallow), A. orientalis (A. swallow), A. orientalis. palawanensis (Palawanen swallow), A. papuensis (A. swallowtail), A. pelewensis (Micronesian swallows), A. rogersi (Indochina swallow), A. salangana (Sweet Swallow), A. sawtelli (cook swallow), A. Spodiopygius (A. swallowtail), A. sp. terraereginae (Australian swallows), A. unicolor (A. swallowtail), A. whiteheadi (Philippine swallow), A. vanikorensis (Mujiana swallow), A. vulcanorum (Sweet Swallow), C.I. esculenta (white swallowtail), C. esculenta linchi (Dr. swallowtail) and C. troglodytes is included.
巣はアナツバメ属の分泌物が固まったものである。分泌物は粘着質の分泌物である。分泌物はアナツバメ属の唾液腺から分泌される。上記アナツバメ属のうちの一の種の巣を原料としてもよい。また二以上の種の巣を組み合わせて原料としてもよい。巣からアナツバメ属の***物及び老廃物並びにその他の不要物を取り除くことが好ましい。 The nest is a solidified secretion of the genus Swallow. Secretions are sticky secretions. Secretions are secreted from the salivary glands of the genus Swallow. A nest of one species of the genus Swallow may be used as a raw material. Further, two or more kinds of nests may be combined and used as a raw material. It is preferred to remove the swallow excreta and wastes and other unwanted matter from the nest.
本実施形態において素材は、かかる巣に酵母を添加するとともに、巣を酵母で発酵して得られる。巣１００ｇに対して、酵母を１０ｇ〜１００ｇ添加することが好ましい。酵母は人工的に育種されたものでもよく、自然界から取得したものでもよい。 In the present embodiment, the material is obtained by adding yeast to such a nest and fermenting the nest with the yeast. It is preferable to add 10 g to 100 g of yeast to 100 g of nest. The yeast may be bred artificially or may be obtained from nature.
上記素材は巣及び酵母の発酵液として得る。発酵前の原料にさらに水分を添加する。水分を添加するために水を添加することが好ましい。巣１００ｇに対して、水を５０ｇ〜１００００ｇ添加することが好ましい。原料を水分とともに発酵させることが好ましい。原料である巣、酵母及び水のみで発酵を行うことが好ましい。 The material is obtained as a nest and yeast fermentation liquid. Add water to the raw material before fermentation. It is preferable to add water to add water. It is preferable to add 50 g to 10,000 g of water to 100 g of the nest. Preferably, the raw material is fermented with moisture. It is preferable to perform fermentation using only the nest, yeast, and water that are the raw materials.
原料である巣に酵母を添加し２４時間以上３年間未満発酵させる。発酵は密閉状態で行う。これにより酵母に嫌気呼吸を促す。発酵槽に充満したガスを定期的に抜くことで、発酵を安定的に行うことができる。発酵後、水分の少なくとも一部を蒸発させることが好ましい。蒸発させることで発酵液を濃縮することが好ましい。 Yeast is added to the nest, which is a raw material, and fermented for 24 hours or more and less than 3 years. Fermentation is performed in a closed state. This promotes anaerobic respiration in the yeast. Fermentation can be stably performed by periodically discharging the gas filled in the fermenter. After fermentation, it is preferable to evaporate at least a part of the water. Preferably, the fermentation liquor is concentrated by evaporation.
上記酵母はＳａｃｃｈａｒｏｍｙｃｅｓ属のＳａｃｃｈａｒｏｍｙｃｅｓ ｃｅｒｅｃｉｓｉａｅ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｂａｙａｎｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｂｏｕｌａｒｄｉｉ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｂｕｌｄｅｒｉ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｃａｒｉｏａｎｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｃａｒｉｏｃｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｃｈｅｖａｌｉｅｒｉ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｄａｉｒｅｎｅｎｓｉｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｅｌｌｉｐｓｏｉｄｅｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｆｌｏｒｅｎｔｉｎｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｋｌｕｙｖｅｒｉ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｍａｒｔｉｎｉａｅ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｎｏｒｂｅｎｓｉｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｐａｒａｄｏｘｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｐａｓｔｏｒｉａｎｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｓｐｅｎｃｅｒｏｒｕｍ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｔｕｒｉｃｅｎｓｉｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓ ｕｎｉｓｐｏｒｕｓ、Ｓａｃｃｈａｒｏｍｙｃｅｓｕｖａｒｕｍ、及びＳａｃｃｈａｒｏｍｙｃｅｓ ｚｏｎａｔｕｓ、Ｓａｃｃｈａｒｏｍｙｃｏｐｓｉｓ属、Ｃａｎｄｉｄａ属のＣａｎｄｉｄａ ｋｅｆｙｒ、Ｃａｎｄｉｄａ ｂｏｍｂｉｃｏｌａ、Ｃａｎｄｉｄａ ｕｔｉｌｉｓ、及びＣａｎｄｉｄａ ｓａｉｔｏａｎａ、Ｚｙｇｏｓａｃｃｈａｒｏｍｙｃｅｓ属のＺｙｇｏｓａｃｃｈａｒｏｍｙｃｅｓ ｒｏｕｘｉｉ、Ｚｙｇｏｓａｃｃｈａｒｏｍｙｃｅｓ ｍｉｃｒｏｅｌｌｉｐｓｏｉｄｅｓ、Ｋｌｕｙｖｅｒｏｍｙｃｅｓ属、Ｓｃｈｉｚｏｓａｃｃｈａｒｏｍｙｃｅｓ属のＳｃｈｉｚｏｓａｃｃｈａｒｏｍｙｃｅｓ ｐｏｍｂｅ、Ｔｏｒｕｌａｓｐｏｒａ属のＴｏｒｕｌａｓｐｏｒａ ｄｅｌｂｒｕｅｃｋｉｉ、Ｐｉｃｈｉａ属のＰｉｃｈｉａ ａｎｏｍａｌａ、Ｐｉｃｈｉａ ｃａｒｉｂｂｉｃａ、Ｐｓｅｕｄｏｘｙｍａ属のＰｓｅｕｄｏｘｙｍａ ｔｓｕｋｕｂａｅｎｓｉｓ、並びにＥｎｄｏｍｙｃｅｓ属のうち一つか、又は二つ以上の組合せからなる酵母でもよい。 The yeast Saccharomyces genus Saccharomyces cerecisiae, Saccharomyces bayanus, Saccharomyces boulardii, Saccharomyces bulderi, Saccharomyces carioanus, Saccharomyces cariocus, Saccharomyces chevalieri, Saccharomyces dairenensis, Saccharomyces ellipsoideus, Saccharomyces florentinus, Saccharomyces kluyveri, Saccharomyces martiniae, Saccharomyces norbensis, Sa charomyces paradoxus, Saccharomyces pastorianus, Saccharomyces spencerorum, Saccharomyces turicensis, Saccharomyces unisporus, Saccharomycesuvarum, and Saccharomyces zonatus, Saccharomycopsis genus, Candida genus Candida kefyr, Candida bombicola, Candida utilis, and Candida saitoana, Zygosaccharomyces genus Zygosaccharomyces rouxii, Zygosaccharomyces microellipsoides , Kluyveromyces spp., Schizosaccharomyces spp Schizosaccharomyces pombe, Torulaspora genus Torulaspora delbrueckii, Pichia genus Pichia anomala, Pichia caribbica, Pseudoxyma genus Pseudoxyma tsukubaensis, and whether one of Endomyces genus, or a yeast consisting of two or more thereof .
上記により得られた発酵液に、防腐効果、日持ち向上機能、及び安定性維持作用のうち少なくとも一つを有する成分を添加する。かかる成分としてパラオキシ安息香酸のエステル類各種、デヒドロ酢酸ナトリウム、ソルビン酸カリウム、ソルビン酸ナトリウム、酢酸ナトリウム及びｐＨ調整剤からなる群から選ばれる一以上の化合物が好ましい。 A component having at least one of an antiseptic effect, a function for improving shelf life, and a function for maintaining stability is added to the fermented liquid obtained above. As such a component, one or more compounds selected from the group consisting of various esters of paraoxybenzoic acid, sodium dehydroacetate, potassium sorbate, sodium sorbate, sodium acetate and a pH adjuster are preferred.
かかる発酵液又は生成液は上述の素材とすることができる。かかる発酵液又は生成液は安定な状態で医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水に代表される組成物に配合することができる。上述の素材は、これらの組成物を製造するための素材として好適に利用できる。これらの組成物に上述の成分を添加してもよい。 Such a fermentation liquor or product liquor can be of the above-mentioned material. Such a fermented liquid or product liquid can be incorporated in a stable state into compositions represented by pharmaceuticals, quasi-drugs, foods for health supplements, foods for nutritional supplements, processed foods, and soft drinks. The above-mentioned materials can be suitably used as materials for producing these compositions. The above components may be added to these compositions.
医薬品においては素材を有効成分として用いてもよい。医薬品の剤形は座剤、軟膏剤、溶液剤、分散剤、乳剤、粉末剤、丸剤、菱形剤、錠剤、トローチ剤、バッカル剤、カプセル製剤、チュウインガム型製剤、繊条基材に支持された剤及び吸入用医薬品製剤のいずれかでもよい。 In pharmaceuticals, a material may be used as an active ingredient. Pharmaceutical dosage forms are supported by suppositories, ointments, solutions, dispersions, emulsions, powders, pills, lozenges, tablets, troches, buccals, capsules, chewing gum, and filament base Or inhalational pharmaceutical preparations.
医薬品が固形製剤であれば、有効成分を、担体、賦形剤、結合剤、崩壊剤、溶出改善剤、膨潤化剤、団結防止剤、付着防止剤及び滑沢剤のうち一以上と混合してもよい。医薬品が液体製剤であれば、有効成分を、溶媒、溶剤、増量剤、等張化剤、溶解補助剤、可溶化剤、乳化剤、懸濁剤、分散剤、粘度調整剤、増粘剤及び容器吸着防止剤のうち一以上と混合してもよい。医薬品は被覆剤でコーティングされていてもよい。被覆形成補助剤を用いてもよい。 If the pharmaceutical is a solid preparation, the active ingredient is mixed with one or more of a carrier, excipient, binder, disintegrant, dissolution improver, swelling agent, anti-bundle agent, anti-adhesion agent and lubricant. You may. When the pharmaceutical is a liquid preparation, the active ingredient is a solvent, a solvent, a bulking agent, a tonicity agent, a solubilizer, a solubilizer, an emulsifier, a suspending agent, a dispersant, a viscosity modifier, a thickener and a container It may be mixed with one or more of the adsorption inhibitors. The medicament may be coated with a coating. A coating forming aid may be used.
医薬品には徐放化剤、持続化用剤、速放化剤、速溶化剤、吸収促進剤、浸透剤、ゲル化剤、凝固促進剤、光安定化剤、保存剤、防腐剤、防湿剤、乳化剤、懸濁剤、分散安定化剤、着色防止剤、脱酸素剤、酸化防止剤、矯味剤、矯臭剤、着色剤、色素、塗料、漂白剤、起泡剤、消泡剤、皮膚刺激防止のため無痛化剤、湿潤剤、保湿剤、帯電防止剤、緩衝剤、ＰＨ調整剤、異性化防止剤、分解防止剤、相互作用防止剤及び副作用軽減剤のうち一以上を添加してもよい。 Pharmaceutical products include sustained release agents, sustaining agents, rapid release agents, rapid solubilizers, absorption enhancers, penetrants, gelling agents, coagulation accelerators, light stabilizers, preservatives, preservatives, and desiccants. , Emulsifier, suspending agent, dispersion stabilizer, coloring inhibitor, deoxidizer, antioxidant, flavoring agent, odorant, coloring agent, pigment, paint, bleaching agent, foaming agent, antifoaming agent, skin irritation For prevention, even if one or more of a soothing agent, a humectant, a humectant, an antistatic agent, a buffer, a pH adjuster, an anti-isomerizing agent, an anti-decomposition agent, an interaction inhibitor and a side effect reducing agent are added. Good.
医薬品の投与経路は経口、注射、体腔、粘膜、経皮及び体内埋込のいずれかでもよい。 The route of administration of the medicament may be any of oral, injection, body cavity, mucous membrane, transdermal and implant.
医薬部外品、健康補助用食品及び栄養補助用食品の形状は上記医薬品と同様のものとすることができる。 The shape of quasi-drugs, foods for health supplements, and foods for nutritional supplements can be the same as those of the above pharmaceuticals.
加工食品は例えばゼリー、グミ、キャンディー、ガム、スナック菓子、焼き菓子、レトルト食品及びインスタント食品のいずれかでもよい。 The processed food may be, for example, any of jelly, gummy, candy, gum, snacks, baked goods, retort foods and instant foods.
上記素材には粘性物質ムチン、Ｎ−アセチルノイラミン酸、多種類のサイトカイン、アナツバメ巣に特有の糖鎖に代表される化合物が含まれている。かかる素材は上述の機能性素材として好適に利用できる。なぜならかかる素材は、上述の症状の予防及び改善の少なくとも一方の効果を有する、又は有することが期待されるからである。 The above materials include a viscous substance, mucin, N-acetylneuraminic acid, various kinds of cytokines, and compounds represented by sugar chains peculiar to the swallow's nest. Such a material can be suitably used as the above-mentioned functional material. This is because such a material has or is expected to have at least one of the effects of preventing and improving the above-mentioned symptoms.
粘性物質ムチンは動物の上皮細胞などから分泌される粘液の主成分として考えられている。 Viscous substance mucin is considered as a main component of mucus secreted from animal epithelial cells and the like.
Ｎ−アセチルノイラミン酸は糖質の一種であるシアル酸を代表する化合物である。Ｎ−アセチルノイラミン酸は自然界で存在するシアル酸の中で最も存在率の高いシアル酸である。特開２００８−１８９６３５号の記載によれば、Ｎ−アセチルノイラミン酸が抗アロディニア作用を有するとともに、神経因性疼痛を改善することが確認されている。 N-acetylneuraminic acid is a compound that represents sialic acid, a type of saccharide. N-acetylneuraminic acid is the most abundant sialic acid among sialic acids found in nature. According to the description of JP-A-2008-189635, it has been confirmed that N-acetylneuraminic acid has an antiallodynic effect and improves neuropathic pain.
上記サイトカインはインターロイキン−６、上皮成長因子(ＥＧＦ)及び繊維芽細胞成長因子(ＦＧＦ)に代表されるサイトカインである。 The cytokine is a cytokine represented by interleukin-6, epidermal growth factor (EGF) and fibroblast growth factor (FGF).
糖鎖は上記生活習慣病に伴う一又は二以上の症状を軽減する働き及びウイルス感染を防ぐ働きのうち少なくともいずれか一方を有する。 The sugar chain has at least one of a function of reducing one or more symptoms associated with the lifestyle-related disease and a function of preventing viral infection.
アナツバメ属が、唾液腺から分泌される粘着質の分泌物で固めて形成した巣を原料とする。巣はＡ．ａｍｅｌｉｓ（ハイイロアナツバメ）、Ａ．ｂｒｅｖｉｒｏｓｔｒｉｓ（ヒマラヤアナツバメ）、Ａ．ｅｌａｐｈｒａ（セイシェルアナツバメ）、Ａ．ｆｒａｎｃｉｃａ（ショクヨウアナツバメ）、Ａ．ｆｕｃｉｐｈａｇａ（ジャワアナツバメ）、Ａ．ｇｅｒｍａｎｉ（マレーアナツバメ）、Ａ．ｈｉｒｕｎｄｉｎａｃｅａ（ヤマアナツバメ）、Ａ．ｉｎｆｕｓｃａｔａ（モルッカアナツバメ）、Ａ．ｉｎｑｕｉｅｔａ（カロリンアナツバメ）、Ａ．ｌｅｕｃｏｐｈａｅｕｓ（タヒチアナツバメ）、Ａ．ｍａｘｉｍａ（オオアナツバメ）、Ａ．ｍｅａｒｎｓｉ（フィリピンムジアナツバメ）、Ａ．ｎｕｄｉｔａｒｓｕｓ（パプアヤマアナツバメ）、Ａ．ｏｃｉｓｔａ（マルケサスアナツバメ）、Ａ．ｏｒｉｅｎｔａｌｉｓ（ガタルカナルアナツバメ）、Ａ．ｐａｌａｗａｎｅｎｓｉｓ（パラワンムジアナツバメ）、Ａ．ｐａｐｕｅｎｓｉｓ（パプアカワアナツバメ）、Ａ．ｐｅｌｅｗｅｎｓｉｓ（ミクロネシアムジアナツバメ）、Ａ．ｒｏｇｅｒｓｉ（インドシナアナツバメ）、Ａ．ｓａｌａｎｇａｎａ（コケアナツバメ）、Ａ．ｓａｗｔｅｌｌｉ（クックアナツバメ）、Ａ．ｓｐｏｄｉｏｐｙｇｉｕｓ（コシジロアナツバメ）、Ａ．ｔｅｒｒａｅｒｅｇｉｎａｅ（オーストラリアアナツバメ）、Ａ．ｕｎｉｃｏｌｏｒ（インドショクヨウアナツバメ）、Ａ．ｗｈｉｔｅｈｅａｄｉ（フィリピンアナツバメ）、Ａ．ｖａｎｉｋｏｒｅｎｓｉｓ（ムジアナツバメ）、Ａ．ｖｕｌｃａｎｏｒｕｍ（ミヤマアナツバメ）、Ｃ．ｅｓｃｕｌｅｎｔａ（シロハラアナツバメ）、Ｃ．ｌｉｎｃｈｉ（ドウクツアナツバメ）及びＣ．ｔｒｏｇｌｏｄｙｔｅｓ（コビトアナツバメ）から選ばれる一以上の種の鳥の巣が好ましい。これらの種を選択することでＮ−アセチルノイラミン酸の含有率を高めることができる。 The nest formed by the genus Swallow is formed by sticky secretions secreted from salivary glands. The nest is A. amelis (A. swallowtail), A. brevirostris (Himalayan Swallows), A. elaphra (Seychelles Swallow), A. franca (A. swallowtail), A. fuciphaga (Swallow Swallow), A. germani (Malayan swallow), A. hirundinacea (Sweet Swallow), A. infuscata (Molkka swallow), A. inquieta (carolin swallow), A. leucophaeus (Tahitian swallows); maxima (Big Swallow), A. meansi (Philippines swallow), A. nuditarsus (Papua yamaswallow), A. ocista (Marquesas swallow), A. orientalis (A. swallow), A. orientalis. palawanensis (Palawanen swallow), A. papuensis (A. swallowtail), A. pelewensis (Micronesian swallows), A. rogersi (Indochina swallow), A. salangana (Sweet Swallow), A. sawtelli (cook swallow), A. Spodiopygius (A. swallowtail), A. sp. terraereginae (Australian swallows), A. unicolor (A. swallowtail), A. whiteheadi (Philippine swallow), A. vanikorensis (Swallow), A. vulcanorum (Sweet Swallow), C.I. esculenta (white swallowtail swallow), C.I. linchi (Dr. swallowtail) and C. Bird nests of one or more species selected from troglodytes are preferred. By selecting these species, the content of N-acetylneuraminic acid can be increased.
巣の乾燥物１００ｇを２００ｇの水に浸す。原料である巣にＳａｃｃｈａｒｏｍｙｃｅｓ ｃｅｒｅｃｉｓｉａｅを６０ｇ添加し発酵させる。発酵期間は４８時間である。発酵は密閉状態で行う。発酵は酵母の嫌気呼吸を伴うものである。発酵槽に充満するガスを定期的に抜くことで、発酵は安定的に行われる。 Immerse 100 g of dried nest in 200 g of water. 60 g of Saccharomyces cerecisiae is added to the nest which is a raw material and fermented. The fermentation period is 48 hours. Fermentation is performed in a closed state. Fermentation involves anaerobic respiration of yeast. Fermentation is performed stably by periodically removing the gas filling the fermenter.
上記の工程で発酵液が生成される。かかる発酵液に、保存料及びｐＨ安定剤を添加することで生成液が得られる。好適な発酵環境において生成液のＮ−アセチルノイラミン酸の含有率は７％以上である。原料である巣、酵母及び水のみで発酵を行うことは好適な発酵環境を実現するのに資する。 A fermentation liquor is generated in the above steps. A product solution is obtained by adding a preservative and a pH stabilizer to the fermentation solution. In a suitable fermentation environment, the content of N-acetylneuraminic acid in the product solution is 7% or more. Fermentation using only the nest, yeast and water, which are the raw materials, contributes to realizing a suitable fermentation environment.
上述の通りＮ−アセチルノイラミン酸が抗アロディニア作用、即ち、神経因性疼痛の改善を有することが確認されている。好適な発酵環境において生成される発酵液は、Ｎ−アセチルノイラミン酸を７％以上含有している。したがって発酵液は抗アロディニア作用を有することが期待される。 As described above, it has been confirmed that N-acetylneuraminic acid has an antiallodynic effect, that is, an improvement in neuropathic pain. The fermentation liquor produced in a suitable fermentation environment contains at least 7% N-acetylneuraminic acid. Therefore, the fermented liquor is expected to have an antiallodynic effect.
以上より、アロディニア又は神経因性疼痛を有する患者に好適量の発酵液又は生成液を投与することで神経因性疼痛の改善が期待できる。このため発酵液又は生成液を含有する組成物はアロディニア又は神経因性疼痛の改善に好適である。 As described above, improvement of neuropathic pain can be expected by administering a suitable amount of a fermentation solution or a production solution to a patient having allodynia or neuropathic pain. Therefore, a composition containing a fermentation liquid or a product liquid is suitable for ameliorating allodynia or neuropathic pain.
また一例において図１に示すように生成液はアミノ酸を含有していた。かかるアミノ酸には９種類の必須アミノ酸が含まれていた。さらに図２に示すように、生成液は必須アミノ酸９種類に加えて、γ−アミノ酸酪酸を含む１８種類のアミノ酸を含有していた。 Further, in one example, the product liquid contained an amino acid as shown in FIG. Such amino acids contained nine essential amino acids. Further, as shown in FIG. 2, the product liquid contained 18 kinds of amino acids including γ-amino acid butyric acid, in addition to 9 kinds of essential amino acids.
また、かかる一例において生成液はビタミン類を含有していた。図３に示すように、かかるビタミン類の組成において、ビタミンＣ（アスコルビン酸）とビタミンＢ群のイノシトールの割合が多かったことが特徴的である。 In such an example, the product liquid contained vitamins. As shown in FIG. 3, the composition of such vitamins is characterized by a high ratio of vitamin C (ascorbic acid) and inositol in the vitamin B group.
実施例１で得られる発酵液に対して、加熱することによってその水分を蒸発させることで、その濃縮液を得ることができる。濃縮液に保存料及びｐＨ安定剤を添加することで生成液を得られる。かかる方法によって生成液中のシアル酸（Ｎ−アセチルノイラミン酸）含有率を、実施例１の生成液よりも高めることができる。 The concentrated liquid can be obtained by heating the fermented liquid obtained in Example 1 to evaporate its water content. A product solution can be obtained by adding a preservative and a pH stabilizer to the concentrated solution. By this method, the content of sialic acid (N-acetylneuraminic acid) in the product solution can be higher than that in the product solution of Example 1.
本実施例の方法により得られた濃縮液も抗アロディニア作用を有することが期待される。このためアロディニア又は神経因性疼痛を有する患者に好適量の濃縮液又は生成液を投与することで神経因性疼痛の改善が期待できる。このため濃縮液又は生成液を含有する組成物はアロディニア又は神経因性疼痛の改善に好適である。 It is expected that the concentrate obtained by the method of this example also has an antiallodynia effect. Therefore, improvement of neuropathic pain can be expected by administering a suitable amount of a concentrated solution or a production solution to a patient having allodynia or neuropathic pain. Therefore, a composition containing a concentrate or a product solution is suitable for ameliorating allodynia or neuropathic pain.
なお、本発明は上記実施形態及び実施例に限られたものではなく、趣旨を逸脱しない範囲で適宜変更及び組み合わせをすることが可能である。以上、実施の形態を参照して本願発明を説明したが、本願発明は上記によって限定されるものではない。本願発明の構成や詳細には、発明のスコープ内で当業者が理解し得る様々な変更をすることができる。 The present invention is not limited to the above embodiments and examples, and can be appropriately changed and combined without departing from the gist. Although the present invention has been described with reference to the exemplary embodiments, the present invention is not limited to the above. Various changes that can be understood by those skilled in the art can be made to the configuration and details of the present invention within the scope of the invention.
この出願は、２０１５年２月３日に出願された日本出願特願２０１５−３１０６５を基礎とする優先権を主張し、その開示の全てをここに取り込む。 This application claims priority based on Japanese Patent Application No. 2015-31065 filed on Feb. 3, 2015, the disclosure of which is incorporated herein in its entirety.
Claims (12)
発酵により得られたＮ−アセチルノイラミン酸の含有率が酵母発酵液中７％以上であり、
発酵に用いる酵母が出芽酵母（Saccharomyces cerevisiae）であるもの。 It is a yeast fermentation liquid of a bird's nest belonging to the genus Swallows,
The content of N-acetylneuraminic acid obtained by fermentation is 7% or more in the yeast fermentation broth ,
The yeast used for fermentation is budding yeast (Saccharomyces cerevisiae) .
請求項１に記載の酵母発酵液。 For use as any of pharmaceuticals, quasi-drugs, dietary supplements, dietary supplements, processed foods and soft drinks,
The yeast fermented liquid according to claim 1.
請求項１又は２に記載の酵母発酵液。 The nest is obtained by performing only the fermentation the yeast and water,
The yeast fermented liquid according to claim 1.
請求項４に記載の組成物。 Any of pharmaceuticals, quasi-drugs, health supplements, nutritional supplements, processed foods and soft drinks,
A composition according to claim 4.
請求項４に記載の組成物。 For ameliorating allodynia or neuropathic pain,
A composition according to claim 4.
請求項４に記載の組成物。 To prevent virus infection,
A composition according to claim 4.
請求項４−７のいずれかに記載の組成物。 The yeast fermentation broth, the nest is obtained by performing the fermentation only by the yeast and water,
A composition according to any one of claims 4 to 7 .
前記原料に水分及び酵母を添加し、ここで前記酵母を出芽酵母（Saccharomyces cerevisiae）とし、さらに質量比を前記原料１００ｇに対して前記水分を５０ｇ〜２００ｇとし、
前記原料を前記水分とともに前記酵母で発酵させる、
素材製造方法。 Using the nest of a bird belonging to the genus Swallows
Water and yeast are added to the raw material, where the yeast is a budding yeast (Saccharomyces cerevisiae), and the mass ratio is 50 g to 200 g with respect to 100 g of the raw material,
Fermenting the raw material with the yeast with the water,
Material manufacturing method.
請求項９に記載の素材製造方法。 Fermentation is performed in a closed state,
The material production method according to claim 9.
請求項１０に記載の素材製造方法。 After fermentation, at least part of the water is evaporated,
The method for producing a material according to claim 10.
請求項９−１１のいずれかに記載の素材製造方法。 The fermentation is the raw material, is carried out only with water and the yeast,
A method for producing a material according to claim 9 .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015031065 | 2015-02-03 | ||
| JP2015031065 | 2015-02-03 | ||
| PCT/JP2015/003205 WO2016125208A1 (en) | 2015-02-03 | 2015-06-25 | Material having swiftlet nest as raw material, composition, and method for producing material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2016125208A1 JPWO2016125208A1 (en) | 2017-11-16 |
| JP6651466B2 true JP6651466B2 (en) | 2020-02-19 |
Family
ID=56563575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572943A Active JP6651466B2 (en) | 2015-02-03 | 2015-06-25 | Production method of yeast fermented liquid, composition and raw material using swallow nest as raw material |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6651466B2 (en) |
| CN (1) | CN107405365B (en) |
| SG (1) | SG11201705801VA (en) |
| WO (1) | WO2016125208A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112931862A (en) * | 2021-03-15 | 2021-06-11 | 北京市小仙炖电子商务有限公司 | Rock candy cubilose and preparation method thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0242962A (en) * | 1988-08-04 | 1990-02-13 | Susumu Murofushi | Production of functional food |
| JPH05214003A (en) * | 1992-02-04 | 1993-08-24 | Mect Corp | Neutrophil migration inhibitor |
| JP4666733B2 (en) * | 2000-08-23 | 2011-04-06 | コンビ株式会社 | Virus infection inhibitor |
| JP4976629B2 (en) * | 2001-09-27 | 2012-07-18 | コンビ株式会社 | Skin promotion agent |
| JP2003259835A (en) * | 2001-12-28 | 2003-09-16 | Oubiken:Kk | Production of fermented product and its utilization |
| JP4401659B2 (en) * | 2002-02-04 | 2010-01-20 | 協和発酵バイオ株式会社 | Insulin secretagogue |
| JP4156507B2 (en) * | 2003-12-26 | 2008-09-24 | 堯 近藤 | Method for producing health food containing porcine placenta |
| JP3984953B2 (en) * | 2003-12-26 | 2007-10-03 | 堯 近藤 | Health food manufacturing method |
| JP2007061058A (en) * | 2005-09-02 | 2007-03-15 | Hideo Yamamoto | Immunity reinforcement food containing sugar chain nutrient and method for producing the same |
| JP4005115B1 (en) * | 2007-02-08 | 2007-11-07 | 日本臓器製薬株式会社 | Pain disease treatment |
| US20100143535A1 (en) * | 2007-07-12 | 2010-06-10 | Hidemasa Motoshima | Method for producing composition containing sialic acid compound |
| CN102334680B (en) * | 2011-08-08 | 2012-12-19 | 邓毛程 | Monascus cubilose and preparation method thereof |
| CN102362637B (en) * | 2011-09-30 | 2013-03-13 | 邓毛程 | Method for removing nitrite in edible bird's nest by using microbial viable bacteria suspension and/or crude enzyme liquid and application |
| JP5914577B2 (en) * | 2014-06-09 | 2016-05-11 | コンビ株式会社 | Collagen production decrease inhibitor, external composition for skin containing the same, and cosmetics |
| CN104146885A (en) * | 2014-07-14 | 2014-11-19 | 武汉中科光谷绿色生物技术有限公司 | Application of N-acetylneuraminic acid hydrate in hair care product |
-
2015
- 2015-06-25 WO PCT/JP2015/003205 patent/WO2016125208A1/en active Application Filing
- 2015-06-25 JP JP2016572943A patent/JP6651466B2/en active Active
- 2015-06-25 CN CN201580074756.3A patent/CN107405365B/en active Active
- 2015-06-25 SG SG11201705801VA patent/SG11201705801VA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107405365B (en) | 2021-06-01 |
| SG11201705801VA (en) | 2017-08-30 |
| JPWO2016125208A1 (en) | 2017-11-16 |
| CN107405365A (en) | 2017-11-28 |
| WO2016125208A1 (en) | 2016-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2009081833A1 (en) | Dried microbial cell or microbial extract containing stabilized (SS) -S-adenosyl-L-methionine and method for producing the same | |
| JP5528629B2 (en) | A polyphosphoric acid composition containing polyphosphoric acid extracted from yeast, a salt of polyphosphoric acid, or a solvate of polyphosphoric acid, and a method for producing the same. | |
| JP2018058903A (en) | Growth hormone secretion promoter | |
| WO2014091138A1 (en) | Chitin or derivatives thereof for the prevention and/or treatment of parasitoses | |
| US8962684B2 (en) | Antioxidant composition | |
| JP6651466B2 (en) | Production method of yeast fermented liquid, composition and raw material using swallow nest as raw material | |
| JP2006075086A (en) | Fermented product obtained from papaya | |
| TW202033205A (en) | Astaxanthin complex and the method thereof | |
| EP0974349A1 (en) | Athletic endurance increasing agent | |
| JP2009269832A (en) | Calcitonin gene-related peptide and composition for accelerating production of insulin-like growth factor-1 | |
| EP2999467B1 (en) | Use of a combination of two compounds for the treatment and/or prevention of bone disorders | |
| JP2023075284A (en) | oral composition | |
| JP2017193497A (en) | Muscle-enhancing agent | |
| JP2012206942A (en) | Skin atrophy improving agent | |
| WO2010027014A1 (en) | Method for improving absorption of s-adenosyl-l-methionine, and composition having improved s-adenosyl-l-methionine absorption | |
| JP7069531B2 (en) | Capsules containing pyrroloquinoline quinone or a salt thereof and branched chain amino acids | |
| JP2022115770A (en) | Low-temperature fermentation decompression extraction method | |
| JP7104193B2 (en) | Muscle builders | |
| JP2018172301A (en) | Oral composition | |
| JP2024100951A (en) | Atrogin-1 expression inhibitor | |
| CN104523736B (en) | A kind of pharmaceutical composition for preventing and treating myocardial infarction and its application | |
| JP2006075085A (en) | Fermented product obtained from parsley | |
| CN118240722A (en) | Lactobacillus paracasei and application thereof in preventing and treating periodontitis | |
| HU190782B (en) | Process for producing pharmaceutical compositions for profilacting and treating negative changes of hygienics on epithelium | |
| JP2020079309A (en) | Muscle-enhancing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190604 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6651466 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |